Prestige BioPharma Limited (KRX:950210)
South Korea
· Delayed Price · Currency is KRW 12,720
+310 (2.50%)
At close: Mar 27, 2025, 3:30 PM KST
Prestige BioPharma Revenue
Prestige BioPharma had revenue of 3.11B KRW in the quarter ending December 31, 2024, with 2,509.26% growth. This brings the company's revenue in the last twelve months to 5.87B, up 1,582.73% year-over-year. In the fiscal year ending June 30, 2024, Prestige BioPharma had annual revenue of 689.08M with 325.77% growth.
Revenue (ttm)
5.87B
Revenue Growth
+1,582.73%
P/S Ratio
136.46
Revenue / Employee
n/a
Employees
n/a
Market Cap
160.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 689.08M | 527.23M | 325.77% |
| Jun 30, 2023 | 161.84M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |